Jak2 (original) (raw)
Latest News for: jak2
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with ...
The Essex Reporter 14 Jun 2026
LLY) today announced new data from the Phase 1 AJX-101 ...
Lilly to present initial clinical data for first-in-class type II JAK2 inhibitor in patients with previously treated myelofibrosis at the 2026 EHA Annual Meeting
PR Newswire 13 Jun 2026
AJ1-11095 is designed to bind JAK2 in its inactive conformation — an approach intended to more completely suppress the aberrant signaling that drives myelofibrosis, in contrast to currently approved JAK2 inhibitors that bind JAK2 in its active state.
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology ...
Nasdaq Globe Newswire 12 Jun 2026
-�JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - ... .
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026
The Eagle-Tribune 12 Jun 2026
- JAK2 V671F poster presentation showcases potential best-in-class properties, including improved selectivity compared with currently approved JAK inhibitors - ... .
- 1
Article Search
tools
You can search using any combination of the items listed below.
Language:
Sort:
Indexed:
Search:
Duplicates: